Dynamic evolution of fibroblasts revealed by single cell RNA sequencing of human pancreatic cancer.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
01 Nov 2024
Historique:
accepted: 29 10 2024
received: 01 12 2023
revised: 21 02 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: aheadofprint

Résumé

Cancer progression and response to therapy are inextricably reliant on the co-evolution of a supportive tissue microenvironment. This is particularly evident in pancreatic ductal adenocarcinoma (PDAC), a tumor type characterized by expansive and heterogeneous stroma. Herein, we employed single cell RNAseq and spatial transcriptomics of normal, inflamed, and malignant pancreatic tissues to contextualize stromal dynamics associated with disease and treatment status, identifying temporal and spatial trajectories of fibroblast differentiation. Using analytical tools to infer cellular communication, together with a newly developed assay to annotate genomic alterations in cancer cells, we additionally explored the complex intercellular networks underlying tissue circuitry, highlighting a fibroblast-centric interactome that grows in strength and complexity in the context of malignant transformation. Our study yields new insights on the stromal remodeling events favoring the development of a tumor-supportive microenvironment and provides a powerful resource for the exploration of novel points of therapeutic intervention in PDAC.

Identifiants

pubmed: 39485038
pii: 749608
doi: 10.1158/2767-9764.CRC-23-0489
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Slavica Dimitrieva (S)

Novartis Institutes for Biomedical Research, Switzerland.

Jon M Harrison (JM)

Massachusetts General Hospital, Boston, MA, United States.

Jonathan Chang (J)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Michelle Piquet (M)

Novartis, Cambridge, United States.

Mari Mino-Kenudson (M)

Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Millicent Gabriel (M)

Novartis, Cambridge, United States.

Vivek Sagar (V)

Novartis, Cambridge, United States.

Heiko Horn (H)

Broad Institute of MIT and Harvard, Harvard Medical School, Cambridge, United States.

Kasper Lage (K)

Broad Institute, Cambridge, MA, United States.

Julie Kim (J)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Shaobu Weng (S)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Anupriya S Kulkarni (AS)

MGH/Harvard Medical School, Boston, United States.

David T Ting (DT)

Massachusetts General Hospital, Charlestown, MA, United States.

Motaz Qadan (M)

Massachusetts General Hospital, Boston, MA, United States.

Peter J Fagenholz (PJ)

Massachusetts General Hospital, Boston, MA, United States.

Cristina R Ferrone (CR)

Cedars-Sinai Medical Center, Los Angeles, United States.

Angelo L Grauel (AL)

Novartis Institutes for Biomedical Research, Cambridge, United States.

Tyler Laszewski (T)

Novartis Institutes for Biomedical Research, United States.

Alina Raza (A)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Markus Riester (M)

Novartis Institutes for BioMedical Research, Cambridge, United States.

Tim Somerville (T)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Joel P Wagner (JP)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Glenn Dranoff (G)

Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Jeffrey A Engelman (JA)

Treeline Biosciences, Watertown, MA, United States.

Audrey Kauffmann (A)

Novartis Institutes for Biomedical Research, Basel, Switzerland.

Rebecca Leary (R)

Novartis Institutes for Biomedical Research, Cambridge, United States.

Andrew L Warshaw (AL)

Massachusetts General Hospital, Boston,, MA, United States.

Keith D Lillemoe (KD)

Massachusetts General Hospital, Boston, MA, United States.

David A Ruddy (DA)

Novartis BioMedical Research, Cambridge, MA, United States.

Andrew S Liss (AS)

Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Viviana Cremasco (V)

Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

Classifications MeSH